博济医药: 关于调整股票期权激励计划行权价格的公告

Core Viewpoint - The company has approved adjustments to the stock option incentive plan's exercise price following the completion of the 2024 annual equity distribution, ensuring compliance with relevant regulations and maintaining shareholder interests [1][9][10] Summary by Sections Company Incentive Plan Overview and Procedures - The company held meetings to review and approve various proposals related to the 2022 stock option incentive plan, including the adjustment of the exercise price and the verification of the list of incentive recipients [1][2][3] Independent Opinions and Verification - Independent directors provided opinions on the incentive plan's benefits for the company's sustainable development and confirmed no harm to the interests of the company and shareholders [2][10] Stock Option Grant and Adjustments - The company granted a total of 2,697,000 stock options to 86 eligible recipients on April 12, 2022, with subsequent adjustments due to resignations and voluntary waivers, resulting in 84 recipients ultimately receiving the options [2][3] - The total number of stock options granted was adjusted multiple times due to various factors, including resignations and the completion of profit distribution plans [3][4][5][6] Exercise Price Adjustments - The exercise price of the stock options was adjusted from 8.75 CNY to 8.74 CNY, and further adjustments were made to 8.73 CNY and then to 8.72 CNY, reflecting the company's annual profit distribution [4][9][10] Impact of Adjustments - The adjustments to the stock option exercise price are not expected to have a significant impact on the company's financial status or operational results, nor will they affect the diligence of the management team [9][10] Legal Opinions and Compliance - Legal opinions confirmed that the adjustments to the stock option exercise price comply with relevant regulations and have received the necessary approvals [10]